In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 13, No. 575 ( 2021-01-06)
Kurzfassung:
Cell-based treatments such as chimeric antigen receptor (CAR) T cells have been finding increasing applications against cancer and other disorders. However, these treatments can have side effects, and it is difficult to stop the activity of an overactive cell-based therapy once it is inside a patient. To improve regulation of CAR T cell treatment, Jan et al . developed a switch-based system for activating and inactivating these cells. T cells with an OFF switch were deactivated using the drug lenalidomide, whereas those with an ON switch required both lenalidomide and a target antigen for activation, allowing control over the timing of T cell activation.
Materialart:
Online-Ressource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abb6295
Sprache:
Englisch
Verlag:
American Association for the Advancement of Science (AAAS)
Publikationsdatum:
2021